{"id":11599,"date":"2016-04-02T21:58:31","date_gmt":"2016-04-02T21:58:31","guid":{"rendered":"https:\/\/clone.arsacs.com\/design-and-synthesis-of-second-generation-voltage-gated-potassium-channel-modifiers-for-correcting-neuronal-dysfunction-as-a-treatment-strategy-for-arsacs-talon-pharmaceuticals\/"},"modified":"2021-07-20T14:42:32","modified_gmt":"2021-07-20T18:42:32","slug":"design-and-synthesis-of-second-generation-voltage-gated-potassium-channel-modifiers-for-correcting-neuronal-dysfunction-as-a-treatment-strategy-for-arsacs-talon-pharmaceuticals","status":"publish","type":"post","link":"https:\/\/arsacs.com\/fr\/design-and-synthesis-of-second-generation-voltage-gated-potassium-channel-modifiers-for-correcting-neuronal-dysfunction-as-a-treatment-strategy-for-arsacs-talon-pharmaceuticals\/","title":{"rendered":"&#8220;Design and Synthesis of Second Generation Voltage-gated Potassium Channel Modifiers for Correcting Neuronal Dysfunction as a Treatment Strategy for ARSACS&#8221; &#8211; Talon pharmaceuticals"},"content":{"rendered":"<p>The overall objective of the project is to devel+op TPS-100 as a first treatment of ARSACS and to identify a second generation drug based on efficacy and knowledge of receptor pharmacology of TPS-100. Our goal is to synthesize a directed library of compounds with varying Kv channel pharmacology with the goal of enhancing activity at Kv1.2, 1.3, 1.4 relative to Kv1.5 and Kv1.1 which are believed to be associated with potential side effects (Table 2).<\/p>\n<p>Duration: one year<br \/>\nGrant: $100,000<br \/>\nContact:<br \/>\nShawn Maddaford, Talon Pharmaceutical Services Inc.<br \/>\n2660 Speakman Drive, Rm A-61 Mississauga, ON L5K 2L1<br \/>\nTel:(416) 479-0738 ext 102<\/p>\n","protected":false},"excerpt":{"rendered":"<p>The overall objective of the project is to devel+op TPS-100 as a first treatment of ARSACS and to identify a second generation drug based on efficacy and knowledge of receptor pharmacology of TPS-100. Our goal is to synthesize a directed library of compounds with varying Kv channel pharmacology with the goal of enhancing activity at [&hellip;]<\/p>\n","protected":false},"author":3,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_et_pb_use_builder":"","_et_pb_old_content":"","_et_gb_content_width":"","inline_featured_image":false,"footnotes":""},"categories":[23],"tags":[],"class_list":["post-11599","post","type-post","status-publish","format-standard","hentry","category-recherche-2016"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>&quot;Design and Synthesis of Second Generation Voltage-gated Potassium Channel Modifiers for Correcting Neuronal Dysfunction as a Treatment Strategy for ARSACS&quot; - Talon pharmaceuticals - ARSACS<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/arsacs.com\/fr\/design-and-synthesis-of-second-generation-voltage-gated-potassium-channel-modifiers-for-correcting-neuronal-dysfunction-as-a-treatment-strategy-for-arsacs-talon-pharmaceuticals\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"&quot;Design and Synthesis of Second Generation Voltage-gated Potassium Channel Modifiers for Correcting Neuronal Dysfunction as a Treatment Strategy for ARSACS&quot; - Talon pharmaceuticals - ARSACS\" \/>\n<meta property=\"og:description\" content=\"The overall objective of the project is to devel+op TPS-100 as a first treatment of ARSACS and to identify a second generation drug based on efficacy and knowledge of receptor pharmacology of TPS-100. Our goal is to synthesize a directed library of compounds with varying Kv channel pharmacology with the goal of enhancing activity at [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/arsacs.com\/fr\/design-and-synthesis-of-second-generation-voltage-gated-potassium-channel-modifiers-for-correcting-neuronal-dysfunction-as-a-treatment-strategy-for-arsacs-talon-pharmaceuticals\/\" \/>\n<meta property=\"og:site_name\" content=\"ARSACS\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=100044457429916\" \/>\n<meta property=\"article:published_time\" content=\"2016-04-02T21:58:31+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2021-07-20T18:42:32+00:00\" \/>\n<meta name=\"author\" content=\"ARSACS\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"ARSACS\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/arsacs.com\\\/fr\\\/design-and-synthesis-of-second-generation-voltage-gated-potassium-channel-modifiers-for-correcting-neuronal-dysfunction-as-a-treatment-strategy-for-arsacs-talon-pharmaceuticals\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/arsacs.com\\\/fr\\\/design-and-synthesis-of-second-generation-voltage-gated-potassium-channel-modifiers-for-correcting-neuronal-dysfunction-as-a-treatment-strategy-for-arsacs-talon-pharmaceuticals\\\/\"},\"author\":{\"name\":\"ARSACS\",\"@id\":\"https:\\\/\\\/arsacs.com\\\/#\\\/schema\\\/person\\\/93b66d6b897bfa131622d04b767b15f1\"},\"headline\":\"&#8220;Design and Synthesis of Second Generation Voltage-gated Potassium Channel Modifiers for Correcting Neuronal Dysfunction as a Treatment Strategy for ARSACS&#8221; &#8211; Talon pharmaceuticals\",\"datePublished\":\"2016-04-02T21:58:31+00:00\",\"dateModified\":\"2021-07-20T18:42:32+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/arsacs.com\\\/fr\\\/design-and-synthesis-of-second-generation-voltage-gated-potassium-channel-modifiers-for-correcting-neuronal-dysfunction-as-a-treatment-strategy-for-arsacs-talon-pharmaceuticals\\\/\"},\"wordCount\":119,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/arsacs.com\\\/#organization\"},\"articleSection\":[\"Recherche 2016\"],\"inLanguage\":\"fr-FR\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/arsacs.com\\\/fr\\\/design-and-synthesis-of-second-generation-voltage-gated-potassium-channel-modifiers-for-correcting-neuronal-dysfunction-as-a-treatment-strategy-for-arsacs-talon-pharmaceuticals\\\/\",\"url\":\"https:\\\/\\\/arsacs.com\\\/fr\\\/design-and-synthesis-of-second-generation-voltage-gated-potassium-channel-modifiers-for-correcting-neuronal-dysfunction-as-a-treatment-strategy-for-arsacs-talon-pharmaceuticals\\\/\",\"name\":\"\\\"Design and Synthesis of Second Generation Voltage-gated Potassium Channel Modifiers for Correcting Neuronal Dysfunction as a Treatment Strategy for ARSACS\\\" - Talon pharmaceuticals - ARSACS\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/arsacs.com\\\/#website\"},\"datePublished\":\"2016-04-02T21:58:31+00:00\",\"dateModified\":\"2021-07-20T18:42:32+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/arsacs.com\\\/fr\\\/design-and-synthesis-of-second-generation-voltage-gated-potassium-channel-modifiers-for-correcting-neuronal-dysfunction-as-a-treatment-strategy-for-arsacs-talon-pharmaceuticals\\\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/arsacs.com\\\/fr\\\/design-and-synthesis-of-second-generation-voltage-gated-potassium-channel-modifiers-for-correcting-neuronal-dysfunction-as-a-treatment-strategy-for-arsacs-talon-pharmaceuticals\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/arsacs.com\\\/fr\\\/design-and-synthesis-of-second-generation-voltage-gated-potassium-channel-modifiers-for-correcting-neuronal-dysfunction-as-a-treatment-strategy-for-arsacs-talon-pharmaceuticals\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/arsacs.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"&#8220;Design and Synthesis of Second Generation Voltage-gated Potassium Channel Modifiers for Correcting Neuronal Dysfunction as a Treatment Strategy for ARSACS&#8221; &#8211; Talon pharmaceuticals\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/arsacs.com\\\/#website\",\"url\":\"https:\\\/\\\/arsacs.com\\\/\",\"name\":\"Fondation de l'Ataxie Charlevoix-Saguenay\",\"description\":\"Research That Heals\",\"publisher\":{\"@id\":\"https:\\\/\\\/arsacs.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/arsacs.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/arsacs.com\\\/#organization\",\"name\":\"ARSACS\",\"url\":\"https:\\\/\\\/arsacs.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/arsacs.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/arsacs.com\\\/wp-content\\\/uploads\\\/2021\\\/06\\\/logo_ARSACS_fr_flat.png\",\"contentUrl\":\"https:\\\/\\\/arsacs.com\\\/wp-content\\\/uploads\\\/2021\\\/06\\\/logo_ARSACS_fr_flat.png\",\"width\":291,\"height\":84,\"caption\":\"ARSACS\"},\"image\":{\"@id\":\"https:\\\/\\\/arsacs.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=100044457429916\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/arsacs.com\\\/#\\\/schema\\\/person\\\/93b66d6b897bfa131622d04b767b15f1\",\"name\":\"ARSACS\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/e3b226aca332e58d41ec45fa04620bcbd869d2e4e661cacde31eeb3ae6a5708d?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/e3b226aca332e58d41ec45fa04620bcbd869d2e4e661cacde31eeb3ae6a5708d?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/e3b226aca332e58d41ec45fa04620bcbd869d2e4e661cacde31eeb3ae6a5708d?s=96&d=mm&r=g\",\"caption\":\"ARSACS\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"\"Design and Synthesis of Second Generation Voltage-gated Potassium Channel Modifiers for Correcting Neuronal Dysfunction as a Treatment Strategy for ARSACS\" - Talon pharmaceuticals - ARSACS","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/arsacs.com\/fr\/design-and-synthesis-of-second-generation-voltage-gated-potassium-channel-modifiers-for-correcting-neuronal-dysfunction-as-a-treatment-strategy-for-arsacs-talon-pharmaceuticals\/","og_locale":"fr_FR","og_type":"article","og_title":"\"Design and Synthesis of Second Generation Voltage-gated Potassium Channel Modifiers for Correcting Neuronal Dysfunction as a Treatment Strategy for ARSACS\" - Talon pharmaceuticals - ARSACS","og_description":"The overall objective of the project is to devel+op TPS-100 as a first treatment of ARSACS and to identify a second generation drug based on efficacy and knowledge of receptor pharmacology of TPS-100. Our goal is to synthesize a directed library of compounds with varying Kv channel pharmacology with the goal of enhancing activity at [&hellip;]","og_url":"https:\/\/arsacs.com\/fr\/design-and-synthesis-of-second-generation-voltage-gated-potassium-channel-modifiers-for-correcting-neuronal-dysfunction-as-a-treatment-strategy-for-arsacs-talon-pharmaceuticals\/","og_site_name":"ARSACS","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=100044457429916","article_published_time":"2016-04-02T21:58:31+00:00","article_modified_time":"2021-07-20T18:42:32+00:00","author":"ARSACS","twitter_card":"summary_large_image","twitter_misc":{"Written by":"ARSACS"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/arsacs.com\/fr\/design-and-synthesis-of-second-generation-voltage-gated-potassium-channel-modifiers-for-correcting-neuronal-dysfunction-as-a-treatment-strategy-for-arsacs-talon-pharmaceuticals\/#article","isPartOf":{"@id":"https:\/\/arsacs.com\/fr\/design-and-synthesis-of-second-generation-voltage-gated-potassium-channel-modifiers-for-correcting-neuronal-dysfunction-as-a-treatment-strategy-for-arsacs-talon-pharmaceuticals\/"},"author":{"name":"ARSACS","@id":"https:\/\/arsacs.com\/#\/schema\/person\/93b66d6b897bfa131622d04b767b15f1"},"headline":"&#8220;Design and Synthesis of Second Generation Voltage-gated Potassium Channel Modifiers for Correcting Neuronal Dysfunction as a Treatment Strategy for ARSACS&#8221; &#8211; Talon pharmaceuticals","datePublished":"2016-04-02T21:58:31+00:00","dateModified":"2021-07-20T18:42:32+00:00","mainEntityOfPage":{"@id":"https:\/\/arsacs.com\/fr\/design-and-synthesis-of-second-generation-voltage-gated-potassium-channel-modifiers-for-correcting-neuronal-dysfunction-as-a-treatment-strategy-for-arsacs-talon-pharmaceuticals\/"},"wordCount":119,"commentCount":0,"publisher":{"@id":"https:\/\/arsacs.com\/#organization"},"articleSection":["Recherche 2016"],"inLanguage":"fr-FR"},{"@type":"WebPage","@id":"https:\/\/arsacs.com\/fr\/design-and-synthesis-of-second-generation-voltage-gated-potassium-channel-modifiers-for-correcting-neuronal-dysfunction-as-a-treatment-strategy-for-arsacs-talon-pharmaceuticals\/","url":"https:\/\/arsacs.com\/fr\/design-and-synthesis-of-second-generation-voltage-gated-potassium-channel-modifiers-for-correcting-neuronal-dysfunction-as-a-treatment-strategy-for-arsacs-talon-pharmaceuticals\/","name":"\"Design and Synthesis of Second Generation Voltage-gated Potassium Channel Modifiers for Correcting Neuronal Dysfunction as a Treatment Strategy for ARSACS\" - Talon pharmaceuticals - ARSACS","isPartOf":{"@id":"https:\/\/arsacs.com\/#website"},"datePublished":"2016-04-02T21:58:31+00:00","dateModified":"2021-07-20T18:42:32+00:00","breadcrumb":{"@id":"https:\/\/arsacs.com\/fr\/design-and-synthesis-of-second-generation-voltage-gated-potassium-channel-modifiers-for-correcting-neuronal-dysfunction-as-a-treatment-strategy-for-arsacs-talon-pharmaceuticals\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/arsacs.com\/fr\/design-and-synthesis-of-second-generation-voltage-gated-potassium-channel-modifiers-for-correcting-neuronal-dysfunction-as-a-treatment-strategy-for-arsacs-talon-pharmaceuticals\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/arsacs.com\/fr\/design-and-synthesis-of-second-generation-voltage-gated-potassium-channel-modifiers-for-correcting-neuronal-dysfunction-as-a-treatment-strategy-for-arsacs-talon-pharmaceuticals\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/arsacs.com\/"},{"@type":"ListItem","position":2,"name":"&#8220;Design and Synthesis of Second Generation Voltage-gated Potassium Channel Modifiers for Correcting Neuronal Dysfunction as a Treatment Strategy for ARSACS&#8221; &#8211; Talon pharmaceuticals"}]},{"@type":"WebSite","@id":"https:\/\/arsacs.com\/#website","url":"https:\/\/arsacs.com\/","name":"Fondation de l'Ataxie Charlevoix-Saguenay","description":"Research That Heals","publisher":{"@id":"https:\/\/arsacs.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/arsacs.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/arsacs.com\/#organization","name":"ARSACS","url":"https:\/\/arsacs.com\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/arsacs.com\/#\/schema\/logo\/image\/","url":"https:\/\/arsacs.com\/wp-content\/uploads\/2021\/06\/logo_ARSACS_fr_flat.png","contentUrl":"https:\/\/arsacs.com\/wp-content\/uploads\/2021\/06\/logo_ARSACS_fr_flat.png","width":291,"height":84,"caption":"ARSACS"},"image":{"@id":"https:\/\/arsacs.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=100044457429916"]},{"@type":"Person","@id":"https:\/\/arsacs.com\/#\/schema\/person\/93b66d6b897bfa131622d04b767b15f1","name":"ARSACS","image":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/secure.gravatar.com\/avatar\/e3b226aca332e58d41ec45fa04620bcbd869d2e4e661cacde31eeb3ae6a5708d?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/e3b226aca332e58d41ec45fa04620bcbd869d2e4e661cacde31eeb3ae6a5708d?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/e3b226aca332e58d41ec45fa04620bcbd869d2e4e661cacde31eeb3ae6a5708d?s=96&d=mm&r=g","caption":"ARSACS"}}]}},"_links":{"self":[{"href":"https:\/\/arsacs.com\/fr\/wp-json\/wp\/v2\/posts\/11599","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/arsacs.com\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/arsacs.com\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/arsacs.com\/fr\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/arsacs.com\/fr\/wp-json\/wp\/v2\/comments?post=11599"}],"version-history":[{"count":1,"href":"https:\/\/arsacs.com\/fr\/wp-json\/wp\/v2\/posts\/11599\/revisions"}],"predecessor-version":[{"id":14898,"href":"https:\/\/arsacs.com\/fr\/wp-json\/wp\/v2\/posts\/11599\/revisions\/14898"}],"wp:attachment":[{"href":"https:\/\/arsacs.com\/fr\/wp-json\/wp\/v2\/media?parent=11599"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/arsacs.com\/fr\/wp-json\/wp\/v2\/categories?post=11599"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/arsacs.com\/fr\/wp-json\/wp\/v2\/tags?post=11599"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}